Company Focus
Moderna
Latest Moderna News
Biotechnology
Cambridge, USA-based mRNA vaccines company Moderna announced that the US Food and Drug Administration (FDA) has approved mFlusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. 6 August 2026
Related News
Insights
Company Spotlight
A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus.
Latest News & Features of interest to Moderna
Biotechnology
South Korean immune-oncology company Vaxcellbio revealed it has signed a strategic memorandum of understanding (MOU) with Canadian biotechnology company Myellama to jointly develop a novel multiple myeloma therapy based on the National Research Council Canada's (NRC) next-generation NK cell engager technology. 4 August 2026
Biotechnology
German biotech BioNTech today reported financial results for the three and six months ended June 30, 2026 and provided an update on its corporate progress. The firm’s shares were down 3.4% at $89.11 in pre-market trading following the results. 4 August 2026
Pharmaceutical
US pharma major Pfizer raised the lower end of its full-year revenue forecast after second-quarter sales and adjusted earnings exceeded analyst expectations, with growth across its non-COVID portfolio offsetting sharp declines for Paxlovid (ritonavir) and Comirnaty. 4 August 2026
Pharmaceutical
German pharma and crop science major Bayer posted second-quarter 2026 sales of 10.87 billion euros ($12.39 billion), up 1.2% as reported and 2.2% on a currency- and portfolio-adjusted basis. Core earnings per share fell 16.7% to 0.95 euros ($1.08), held back by a normalization in tax expense and weaker earnings in the group's reconciliation line. 4 August 2026
Biotechnology
USA-based techbio Receptor.AI and Sethera Therapeutics have formed a research alliance combining computational modeling with peptide library screening to identify potential drugs for hard-to-drug targets. 3 August 2026
Pharmaceutical
Australia is the latest country to undertake a review of the benefits and risks of Tavneos (avacopan), the regulator Therapeutic Goods Administration (TGA) announced today. 3 August 2026
Pharmaceutical
India’s pharmaceutical sector is undergoing a structural shift, with diabetes therapies and cardiac care driving growth well above the broader market. 3 August 2026
Biotechnology
USA-based biotech major Amgen has disclosed what it called a material cybersecurity incident, in which hackers exfiltrated company data, including proprietary information and patient protected health information, from cloud environments run by third-party providers. The company revealed the breach in a filing with the US Securities and Exchange Commission (SEC). 3 August 2026
Biotechnology
UK and USA-based biotech Tiziana Life Sciences has announced quantitative PET imaging results from the third patient with multiple system atrophy (MSA) in the Phase II clinical trial treated with intranasal foralumab to complete dosing. 3 August 2026
Biotechnology
M&A news last week saw Belgo-Dutch firm argenx announce a deal to acquire Forte Biosciences, and its FB102, for around $2.2 billion, and Johnson & Johnson inked a collaboration with Sail Biosciences including an option to buy the company. UK pharma major GSK announced better than expected 2nd-qtr financials and growth plans. Also, the US Food and Drug Administration (FDA) issued negative briefing documents on US biotech Capricor Therapeutics’ deramiocel for the treatment of Duchenne muscular dystrophy. 2 August 2026
Latest In Brief for Moderna
Biotechnology
US pharma major AbbVie is nearing an all-cash deal to acquire clinical-stage biotech Apogee Therapeutics for roughly $10.9 billion. 20 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze